AnaptysBio, Inc. ANAB Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Anaptys Bio Generated Anti PD1Jemperli Dostarlimab | $516M+100% | $258M+24.0% | $208M+20.2% | $173M— | —— | |
| License | $0-100% | $9.6M— | —— | —— | —— | |
| General And Administrative Expense by Product | ||||||
| External Expenses | $24.52M+36.7% | $17.94M+35.2% | $13.28M-2.1% | $13.56M+0.8% | $13.45M+34.1% | |
| Internal Expenses | $38.29M+16.8% | $32.79M+2.9% | $31.87M-0.2% | $31.94M+3.9% | $30.73M-5.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AnaptysBio, Inc. break its business down?
- AnaptysBio, Inc. (ANAB) reports revenue by business across 2 parts — Biopharma Company and Royalty Management Company. Each is extracted from the segment footnotes and tracked over time.
- Where does AnaptysBio, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AnaptysBio, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.